Potential drug interactions in patients given antiretroviral therapy

Abstract

Objective:to investigate potential drug-drug interactions (PDDI) in patients with HIV infection on antiretroviral therapy. Methods:a cross-sectional study was conducted on 161 adults with HIV infection. Clinical, socio demographic, and antiretroviral treatment data were collected. To analyze the potential drug interactions, we used the software Micromedex(r). Statistical analysis was performed by binary logistic regression, with a p-value of ≤0.05 considered statistically significant. Results:of the participants, 52.2% were exposed to potential drug-drug interactions. In total, there were 218 potential drug-drug interactions, of which 79.8% occurred between drugs used for antiretroviral therapy. There was an association between the use of five or more medications and potential drug-drug interactions (p = 0.000) and between the time period of antiretroviral therapy being over six years and potential drug-drug interactions (p < 0.00). The clinical impact was prevalent sedation and cardiotoxicity. Conclusions:the PDDI identified in this study of moderate and higher severity are events that not only affect the therapeutic response leading to toxicity in the central nervous and cardiovascular systems, but also can interfere in tests used for detection of HIV resistance to antiretroviral drugs.

Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety

“…DDIs remain one of the important therapeutic challenges in hospitalized patients (Zwart-van-Rijkom et al, 2009). The overall prevalence of pDDIs in our study was higher (62.3%) as compared to the prevalence among patients with other diseases such as HIV (52.2%)(Santos et al, 2016), liver cirrhosis (21.5%) (Franz et al, 2012), and hypertension (48%) (Subramanian et al, 2018). Moreover, our prevalence was lower in comparison with studies in patients with hemodialysis (89.1%) (Al-ramahi et al, 2016), hematopoietic stem cell transplantation (82.5%) (Trevisan et al, 2015), and CKD (95.9%) (Olumuyiwa et al, 2017).…”

Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?

“…The area remains poorly addressed, locally as well as globally, therefore such studies are needed. The overall prevalence of pDDIs in the current study was higher (73.1%) as compared with that among patients with certain diseases such as HIV (52.2%) [22], liver cirrhosis (21.5%) [23], hypertension (48%) [24], and pediatric patients with respiratory diseases (38.9%) [25]. While, this prevalence of pDDIs is lower in comparison with that among patients with chronic obstructive pulmonary disease (90%) [26] and hemodialysis (89.1%) [27].…”

Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team

“…Coadministration of ART with other medications can result in significant changes in serum levels of the drugs, many of which are associated with preventable adverse effects (19).…”